Therapy with immunoglobulin: applications for monoclonal antibodies.
The ability of antibodies to recognize specific antigenic targets and trigger responses from the immune system has made them attractive candidates as therapeutic agents. Monoclonal and recombinant technology have made possible the development of a new class of therapeutic and diagnostic agents that combine the exquisite specificity of antibodies with biologic compatibility and protracted half-lives. This technology is just beginning to be explored and considerable evolution may be expected in the next few decades.
Stowell
Christopher P
CP
Blood Transfusion Service, Massachusetts General Hospital 02114-2696, USA. cstowell@partners.org
D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068818:Cetuximab; D000077561:Daclizumab; D006801:Humans; D006822:Hybrid Cells / Q000378:metabolism; D006825:Hybridomas / Q000378:metabolism; D007074:Immunoglobulin G / Q000627:therapeutic use; D007136:Immunoglobulins; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007202:Indicators and Reagents; D000069285:Infliximab; D000069442:Natalizumab; D018579:Patient Selection; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D007136:Immunoglobulins; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007202:Indicators and Reagents; D000069442:Natalizumab; D000069283:Rituximab; D000069285:Infliximab; C101315:Capromab Pendetide; D000077561:Daclizumab; D000068818:Cetuximab